Bannerman Wealth Management Group LLC Sells 565 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Bannerman Wealth Management Group LLC reduced its stake in Alnylam Pharmaceuticals by 20.7% in Q2, selling 565 shares and retaining a total of 2,164 shares valued at approximately $706,000.
• Alnylam's CEO Yvonne Greenstreet sold 6,979 shares for over $3 million, significantly decreasing her ownership by 11.04%.
• Analysts have recently increased price targets for Alnylam Pharmaceuticals, with the consensus rating being a "Moderate Buy" and an average target price of $439.58.

Bannerman Wealth Management Group LLC decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 20.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,164 shares of the biopharmaceutical company's stock after selling 565 shares during the period. Alnylam Pharmaceuticals accounts for approximately 0.5% of Bannerman Wealth Management Group LLC's holdings, making the stock its 20th largest position. Bannerman Wealth Management Group LLC's holdings in Alnylam Pharmaceuticals were worth $706,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in shares of Alnylam Pharmaceuticals by 17.9% during the 2nd quarter. GAMMA Investing LLC now owns 726 shares of the biopharmaceutical company's stock worth $237,000 after purchasing an additional 110 shares during the last quarter. Park Avenue Securities LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $680,000. Sowell Financial Services LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $201,000. Farther Finance Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 57.3% in the second quarter. Farther Finance Advisors LLC now owns 379 shares of the biopharmaceutical company's stock valued at $123,000 after acquiring an additional 138 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in Alnylam Pharmaceuticals by 176.1% in the second quarter. Assenagon Asset Management S.A. now owns 17,686 shares of the biopharmaceutical company's stock valued at $5,767,000 after acquiring an additional 11,281 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,979 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the sale, the chief executive officer directly owned 56,221 shares in the company, valued at $25,483,292.67. This represents a 11.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dennis A. Ausiello sold 31,448 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at approximately $397,724.38. The trade was a 97.18% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 75,594 shares of company stock worth $33,968,256. Company insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on ALNY. The Goldman Sachs Group lifted their price target on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a "buy" rating in a report on Tuesday, September 16th. BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Oppenheimer upgraded Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price objective for the company in a report on Monday, August 4th. Scotiabank increased their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research note on Friday, August 1st. Finally, Bank of America boosted their price target on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a "buy" rating in a research note on Wednesday, September 17th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $439.58.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ:ALNY opened at $454.41 on Wednesday. The firm has a market cap of $59.56 billion, a P/E ratio of -183.97 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The business has a fifty day simple moving average of $420.78 and a 200 day simple moving average of $327.63. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the company posted ($0.13) EPS. The business's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.